CNS Drugs provides researchers and healthcare professionals with essential information on the most important aspects of drug therapies used for the management of neurological and psychiatric disorders.
Via a program of reviews and original research articles, the journal addresses major issues relating to drug therapy of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of neurological and psychiatric disorders; and the practical management of specific clinical situations.
CNS Drugs offers a range of additional enhanced features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers in understanding important medical advances. The journal also provides the option to include various other types of enhanced features including slide sets, videos and animations. All enhanced features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.
Long-Term Neuropsychological Outcomes from an Open-Label Phase I/IIa Trial of 2-Hydroxypropyl-β-Cyclodextrins (VTS-270) in Niemann-Pick Disease, Type C1
Letter to the Editor
Hans-Christoph Diener (June 2019)
- Journal Title
- CNS Drugs
- Volume 1 / 1994 - Volume 33 / 2019
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors
To view the rest of this content please follow the download PDF link above.